US Supreme Court to look at what adverse events need to be disclosed to shareholders
This article was originally published in Scrip
Executive Summary
The US Supreme Court has agreed to review a case known as Matrixx Initiatives Inc v Siracusano, which addresses the question of whether Matrix, a company marketing the homeopathic intranasal cold therapy Zicam (zinc gluconate), had a duty to publicly disclose adverse drug event reports to shareholders even though the events were not statistically significant.